| Literature DB >> 34934098 |
Nessma A El-Zawawy1, Mahy M Mona2.
Abstract
Snail mucus is composed of bioactive compounds thought to have different biological properties for the treatment of some skin problems. Although Helix aspersa mucus is used in several cosmetic products, a detailed characterization of Eremina desertorum mucus composition and its biological activities is still missing. Mucus extracts (MEs) from H. aspersa and E. desertorum were prepared and tested for their antimicrobial and anti-inflammatory activities with their potencies in wound healing. Also, chemical characterization was performed by GC-MS analysis. Results showed that ME of E. desertorum gave higher inhibitory activity against resistant strains related to burn wound infections compared to ME of H. aspersa. Additionally, it revealed a significant anti-inflammatory activity. Moreover, we found that ME of E. desertorum lacked cytotoxicity and was able to significantly induce cell proliferation and migration through up-regulation of TGF-β1 and VEGF gene expression. Our results suggested that MEs of E. desertorum have higher biological effects than H. aspersa, which are attributable to antimicrobial, anti-inflammatory activities, cell proliferation and pave the way for further investigating its potential effect as a human therapeutic agent.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34934098 PMCID: PMC8692597 DOI: 10.1038/s41598-021-03664-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Antimicrobial activities of ME of E. desertorum by agar well diffusion method. (A) PA-9; (B) EC-3; (C) KP-1; (D) SA-17; (E) AN-05; (F) RS; (G) TH; (H) CA-11.
Antimicrobial activity of MEs of selected snails.
| Snails | Microorganisms | Zone of inhibition (mm) | MIC (µg/ml) | DRPs | Resistance type | ||||
|---|---|---|---|---|---|---|---|---|---|
| Different concentrations (µg/ml) | |||||||||
| 10 | 20 | 30 | 40 | 50 | |||||
| 0.0 ± 0.0 | 8 ± 0.1 | 11.2 ± 0.1 | 15.5 ± 0.06 | 15.8 ± 0.06 | 15 | AX, CAZ, FEP, ATM, CRO, IPM, CIP, SXT, C, CN, TOB, K, CT[ | MDR | ||
| 9.5 ± 0.0 | 13.9 ± 0.1 | 18.5 ± 0.1 | 22.8 ± 0.06 | 25.5 ± 0.06 | 7 | ||||
| 0.0 ± 0.0 | 7 ± 0.1 | 10 ± 0.1 | 15.5 ± 0.06 | 16.8 ± 0.06 | 20 | AX, CAZ, FEP, ATM, VA, TZP, AMC, IPM, CIP, SXT, C, TOB, K, CT[ | MDR | ||
| 10.5 ± 0.0 | 14.5 ± 0.1 | 20.5 ± 0.1 | 25.6 ± 0.06 | 30.5 ± 0.06 | 5 | ||||
| 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | ND | PIP, AMC, TZP, CTX, NA, AK, VA, ATM, C, CIP, CN, CRO, CTX, IPM, K, SXT, TE[ | PDR | ||
| 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | ND | ||||
| 0.0 ± 0.0 | 8.5 ± 0.06 | 10 ± 0.06 | 14.9 ± 0.1 | 18.2 ± 0.1 | 15 | PIP, AMC, TZP, CTX, CFP, NA, AK, AX, C, CIP, CN, CTX, FEP, IPM, K, SXT, TE[ | PDR | ||
| 10 ± 0.0 | 16.5 ± 0.1 | 19 ± 0.1 | 21.8 ± 0.06 | 28 ± 0.06 | 5 | ||||
| 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 6.2 ± 0.06 | 8 ± 0.1 | 32 | AMB, ITC, CLT, MIZ, FLC, TRB[ | MDR | ||
| 10.8 ± 0.0 | 20.8 ± 0.0 | 34.6 ± 0.06 | 47.2 ± 0.06 | 55.2 ± 0.1 | 7 | ||||
| 0.0 ± 0.0 | 0.0 ± 0.0 | 9.2 ± 0.0 | 12.6 ± 0.0 | 14 ± 0.1 | 25 | AMB, ITC, CLT, MIZ, FLC, NYT[ | MDR | ||
| 8.5 ± 0.1 | 10.8 ± 0.1 | 27.5 ± 0.1 | 40.8 ± 0.0 | 52.6 ± 0.0 | 10 | ||||
| 0.0 ± 0.0 | 0.0 ± 0.0 | 10 ± 0.0 | 14.6 ± 0.0 | 18 ± 0.1 | 25 | AMB, ITC, CLT, MIZ, FLC, MCFG, NYT[ | MDR | ||
| 8 ± 0.1 | 10.2 ± 0.1 | 25.5 ± 0.1 | 38.8 ± 0.0 | 49.6 ± 0.0 | 10 | ||||
| 0.0 ± 0.0 | 3 ± 0.0 | 8.6 ± 0.06 | 10.8 ± 0.1 | 13 ± 0.06 | 20 | AMB, ITC, CLT, MIZ, FLC, MCFG, NYT, TRB[ | PDR | ||
| 7.8 ± 0.0 | 15.2 ± 0.1 | 26.8 ± 0.1 | 38.6 ± 0.1 | 49.2 ± 0.06 | 12 | ||||
| ANOVA | < 0.001 | < 0. 001 | < 0. 001 | < 0. 001 | < 0. 001 | – | – | – | |
| F | 34.15 | 64,095 | 154.4 | 73,302 | 36,211 | – | – | – | |
Values are the mean of three replicates ± SD. P value < 0.05 is considered significant.
Data obtained from our previous studies[12,20,25,26].
1: H.aspersa; 2: E. desertorum; ND, Not detected; MIC, Minimum inhibitory concentration; DRPs, Drug-resistance patterns; MDR, Multi-drug resistance; PDR, Pan-drug resistance; AX, Amoxicillin; CAZ, Ceftazidime; FEP, Cefepime; ATM, Aztreonam, CRO, Ceftriaxone; IMP, Imipenem; CIP, Ciprofloxacin; SXT, Cotrimoxazole; C, Chloramphenicol; CN, Gentamicin; TOB, Tobramycin; K, Kanamycin; CT, Colistin sulfate; PIP, Piperacillin; AMC, Amoxicillin/clavulanic acid; TZP, Pipracillin/tazobactam; CTX, Cefotaxime; CFP, Cefoperazone; NA, Nalidixic acid; AK, Amikacin; TE, Tetracycline; VA, Vancomycin; AMB, Amphotericin; FLC, Fluconazole; ITC, Itraconazole; CLT, Clotrimazole; MIZ, Miconazole; MCFG, Micfungin; NYT, Nystatin; TRB, Terbinafine.
Figure 2Anti-inflammatory activities of MEs of both snails compared to aspirin. Results represent the average of three independent experiments ± SD. *p < 0.05.
Figure 3Cytotoxicity evaluation of MEs of both selected snails. HSF cells were exposed to 300 µg/ml of MEs of both selected snails and cell viability was examined by SRB assay. (A) Representative images with magnification of (10 ×) taken by light microscopy of HSF cells untreated and treated with 300 µg/ml of both selected strains at 48 h. (B) Cell viability was calculated at 24, 48 and 72 h compared to untreated cells (control), DMSO (10%) and (1%) were used as positive and vehicle controls of cell death, respectively. Results represent the average of three independent experiments ± SD. *p < 0.05.
Figure 4Scratch-wound healing assay. (A) Percentage of wound closure at 0, 24, 48 h in the absence and presence of MEs of both selected snails (300 µg/ml). Results represent the average of three independent experiments ± SD. *p < 0.05. (B) Microscopical representative images for wound healing of MEs of both selected snails.
Figure 5Effect of MEs of both snails (300 µg/ml) on the expression of Tgfβ1 and Vegf-A genes in HSF cells after 48 h. Results represent the average of three independent experiments ± SD. *p < 0.05.
Chemical constituents ME of E. desertorum using GC–MS.
| Peak | Name of compound | Molecular formula | Molecular weight (g/mol) | Retention time (min) | Peak area (%) |
|---|---|---|---|---|---|
| 1 | Bis(trimethylsiloxy)methylsilane | C7H21O2Si3 | 221.50 | 5.376 | 1.11 |
| 2 | 4-Trimethylsilyl-9,9-dimethyl-9-silafluorene | C17H22Si2 | 282.5 | 5.620 | 1.72 |
| 3 | 3,6,9,12,15,18-Hexaoxanonadecan-1-ol, TMS derivative | C16H36O7Si | 368.54 | 5.829 | 0.57 |
| 4 | Decamethyl cyclo penta siloxane | C10H30O5Si5 | 370.77 | 5.984 | 2.47 |
| Methyl 1,2-benzisothiazole-3-acetate | C10H9NO2S | 207.25 | 7.507 | 5.39 | |
| 6 | 4-(Nonafluoro-tert-butyl) nitrobenzene | C10H4F9NO2 | 341.13 | 7.613 | 2.07 |
| 7 | Benzeneacetaldehyde, .alpha.-(methoxymethylene)-4-nitro- | C10H9NO4 | 207.18 | 7.937 | 1.54 |
| 8 | Ehoxytris(trimethylsiloxy)silane | C11H32O4Si4 | 340.71 | 7.978 | 0.63 |
| 9 | 1-(3,6,6-Trimethyl-1,6,7,7a-tetrahydrocyclopenta[c]pyran-1-yl)ethanone | C13H18O2 | 206.28 | 8.025 | 1.73 |
| 10 | 5H-Dibenzo[a,d]cyclohepten-5-amine | C15H13N | 207.27 | 8.055 | 2.05 |
| 11 | Methyl 1,2-benzisothiazole-3-acetate | C10H9NO2S | 207.25 | 8.989 | 1.23 |
| 12 | Methyl 2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate | C11H13NO3 | 207.23 | 9.084 | 1.97 |
| Phthalic acid, 7-bromoheptyl ethyl ester | C17H23BrO4 | 371.3 | 9.148 | 7.29 | |
| 14 | Diethyl Phthalate | C6H4(COOC2H5)2 | 222.24 | 9.250 | 3.26 |
| 15 | Prop-2-enoic acid, 2-cyano-3-(3-methyl-2-thienyl)-, methyl ester | C10H9NO2S | 207.25 | 9.302 | 1.44 |
| 16 | Isophthalic acid, 2-methoxyethyl isobutyl ester | C15H20O5 | 280.32 | 9.369 | 1.64 |
| 17 | Prop-2-enoic acid, 2-cyano-3-(3-methyl-2-thienyl)-, methyl ester | C10H9NO2S | 207.25 | 9.467 | 1.24 |
| 18 | 7,7,9,9,11,11-Hexamethyl-3,6,8,10,12,15-hexaoxa-7,9,11-trisilaheptadecane | C14H36O6Si3 | 384.69 | 9.904 | 2.72 |
| 19 | Silicic acid, diethyl bis(trimethylsilyl) ester | C10H28O4Si3 | 296.58 | 10.004 | 1.63 |
| 20 | Benzene, [1-(3-butenylthio)-2-nitroethyl]- | C12H15NO2S | 237.32 | 10.506 | 2.31 |
| 21 | Benzothiophene-3-carboxylic acid,4,5,6,7-tetrahydro-2-amino-6-ethyl-, ethyl ester | C13H19NO2S | 253.36 | 11.107 | 3.58 |
| 22 | Propanephosphonic acid, bis(trimethylsilyl) ester | C9H25O3PSi2 | 268.44 | 11.291 | 3.68 |
| 3H-1,2,4-triazole-3-thione, 4,5-dihydro-4,5-diphenyl- | C14H11N3S | 253.32 | 11.483 | 6.07 | |
| 24 | Cyclotrisiloxane, hexamethyl- | C6H18O3Si3 | 222.46 | 11.686 | 0.95 |
| 25 | 1,2-Bis(trimethylsilyl)benzene | C12H22Si2 | 222.47 | 11.712 | 0.34 |
| 26 | 6-Methyl-2-(3-nitrophenyl)imidazo[1,2 a]pyridine | C14H11N3O2 | 253.26 | 12.052 | 1.83 |
| 27 | Phthalic acid, 7-bromoheptyl ethyl ester | C17H23BrO4 | 371.3 | 12.130 | 2.84 |
| 28 | Diethyl Phthalate | C12H14O4 | 222.24 | 12.163 | 4.26 |
| 29 | Benzothiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-amino-6-ethyl -, ethyl ester | C13H19NO2S | 353.36 | 12.267 | 4.12 |
| 30 | 6Methyl2(3nitrophenyl)imidazo[1,2-a]pyridine | C14H11N3O2 | 253.26 | 12.561 | 1.13 |
| 31 | Methyl 6,6,8,8,10,10-hexamethyl-3-oxo-2,5,7,9,11-pentaoxa-6,8,10-trisilatridecan-13-oate | C12H28O8Si3 | 348.60 | 12.693 | 1.58 |
| 32 | 1,1,1,3,5,5,5-Heptamethyltrisiloxane | C7H21O2Si3 | 221.50 | 13.830 | 0.45 |
| 33 | Cyclohexa-2,5-diene-1,4-dione, 2-methyl-5-(4-morpholinyl)- | C11H13NO3 | 207.23 | 13.848 | 0.19 |
| 34 | Methyltris(trimethylsiloxy)silane | C10H30O3Si4 | 310.68 | 14.040 | 0.75 |
| 35 | 9H-Fluorene-4-carboxylic acid, 9-oxo-, (2,6-dimethylphenyl)amide | C22H17NO2 | 327.4 | 14.270 | 0.84 |
| 36 | Benzothiophene-3-carboxylic acid, 4,5,6,7-tetrahydro -2-amino-6-ethyl -, ethyl ester | C13H19NO2S | 353.36 | 15.820 | 2.10 |
Chemical Constituents ME of H. aspersa using GC–MS.
| Peak | Name of compound | Molecular formula | Molecular weight (g/mol) | Retention time (min) | Peak area (%) |
|---|---|---|---|---|---|
| 1 | (Z)-2-Heptene | C7H14 | 98.1861 | 5.163 | 1.11 |
| 2 | 4H-Thiopyran-4-one, tetrahydro-, 1,1-dioxide | C5H8O3S | 148.18 | 5.186 | 2.12 |
| Thiophene, 3-(decyloxy)tetrahydro-, 1,1-dioxide | C14H28O3S | 276.44 | 5.245 | 4.85 | |
| Thiophene, 3-(decyloxy)tetrahydro-, 1,1-dioxide | C14H28O3S | 276.44 | 5.300 | 6.12 | |
| 5 | 2-Ethylacridine | C15H13N | 207.27 | 5.369 | 1.73 |
| 6 | Auramine | C17H21N3 | 267.37 | 5.621 | 2.18 |
| 7 | Methyltris(trimethylsiloxy)silane | C10H30O3Si4 | 310.68 | 5.854 | 3.00 |
| 8 | N-(Trifluoroacetyl)-N,O,O',O''-tet rakis(trimethylsilyl)norepinephrin | C22H42F3NO4Si4 | 553.9 | 5.985 | 3.07 |
| 4-(Nonafluoro-tert-butyl) nitrobenzene | C10H4F9NO2 | 341.13 | 7.526 | 4.86 | |
| 10 | Cyclohexasiloxane, dodecamethyl- | C12H36O6Si6 | 444.92 | 7.614 | 3.57 |
| 11 | 3-Isopropoxy-1,1,1,5,5,5-hexamethy l-3-(trimethylsiloxy)trisiloxane | C12H34O4Si4 | 354.74 | 8.857 | 4.14 |
| 12 | Mercaptoethanol, 2TMS derivative | C8H22OSSi2 | 222.50 | 9.916 | 1.95 |
| 13 | Octasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl- | C16H48O7Si8 | 577.2 | 10.011 | 2.13 |
| 14 | N-(2-Acetylcyclopentylidene)cyclohexylamine | C13H21NO | 207.31 | 10.507 | 2.16 |
| 15 | 6-Chloro-4-phenyl-2-propylquinolin | C18H16ClN | 281.8 | 5.163 | 1.11 |